ACI 30th Annual Conference on Drug & Medical Device Litigation
Event | 12.04.25, 3:15 PM EST - 4:15 PM EST | CLE Offered
Address
New York Marriott Marquis
1535 Broadway
New York, NY 10036
Dan Campbell with Speak on the panel "Mastering MDL Case Management: What Proposed Rule 16.1 Really Means for Consolidated Litigation."
Rule 16.1 attempts to guide early case management in MDLs, impacting litigation pace and costs. Permissive language like “should” instead of “must”, could lead to inconsistent applications. This panel will explore the rule’s anticipated impact and implications for procedures. Topics of discussion will include:
- Understanding how the new rule will be applied in different case settings and MDL proceedings
- Exploring the permissive, rather than mandatory language: does it eliminate the current uncertainty of MDL processes and procedures?
- Determining if the Rule limits or expands the discretion that District Judges have?
- Deciding if the Rule can help stem the tide of mass filings of meritless claims
- Reviewing the nonbinding language to determine if it only serves to perpetuate the uncertainty that exists in the world of MDLs?
For more information, please visit these areas: Mass Tort, Product, and Consumer Litigation, Class Action Defense, Litigation and Trial, Product Liability Class Actions, Medical Devices, Product Risk Management, National Coordinating Counsel and Complex Litigation, Life Sciences
Participants
Insights
Event | 10.08.26
Crowell & Moring and King’s College London Seventh EU Competition Law Conference
Join us at the Seventh EU Competition Law Conference, co-hosted by Crowell & Moring and King's College London. This year's conference offers an authoritative and comparative Europe–US perspective on the latest developments in competition law.
